Framework to Select Multi-Cancer Detection Assays in the National Cancer Institute’s Vanguard Study
Significant resources are required for large-scale cancer screening trials; therefore, promising technologies must be prioritized for inclusion in a definitive trial. NCI's assay selection framework can be used and repurposed by other networks and institutions.
Authors
- David B. Edelman (ORCID: https://orcid.org/0000-0002-5329-6875)
- Hormuzd A. Katki (ORCID: https://orcid.org/0000-0003-2002-0095)
- A. Martin
- Lyndsay N. Harris (ORCID: https://orcid.org/0000-0002-9774-6719)
- Philip C. Prorok (ORCID: https://orcid.org/0000-0002-2126-5847)
- Anthony Dickherber (ORCID: https://orcid.org/0000-0001-7265-8053)
- Lori M. Minasian
- Elyse LeeVan (ORCID: https://orcid.org/0000-0002-2581-9747)
- Sarah M. Temkin (ORCID: https://orcid.org/0000-0002-6472-2745)
- Amanda L. Skarlupka (ORCID: https://orcid.org/0000-0002-3654-9076)
- Paul F. Pinsky (ORCID: https://orcid.org/0000-0002-0350-3282)
- David F. Ransohoff (ORCID: https://orcid.org/0000-0002-2200-039X)
- Christos Patriotis (ORCID: https://orcid.org/0000-0001-6441-776X)
- Wendy S. Rubinstein (ORCID: https://orcid.org/0000-0002-8790-9959)
- Erin Lavik (ORCID: https://orcid.org/0000-0002-0644-744X)
- Wade E. Bolton
- Mary Jane Ong
Institutions
- University of North Carolina at Chapel Hill (US)
- National Institutes of Health (US)
- VentureWell (US)
- National Cancer Institute (US)
Publication Details
- Journal
- Cancer Epidemiology Biomarkers & Prevention
- Published
- 2025-08-04
- DOI
- https://doi.org/10.1158/1055-9965.epi-25-0903
- Citations
- 5
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 4.68
Funders
- U.S. Department of Health and Human Services
- Division of Cancer Prevention, National Cancer Institute
- Leidos
- National Institutes of Health
- National Cancer Institute